文献速递核素与放射性配体治疗肿瘤 PET/CT

前列腺癌放射性核素治疗:从单药到联合PSMA诊疗一体化

Radionuclide Therapy in Prostate Cancer: From Standalone to Combination PSMA Theranostics.
PubMed 文献 · J Nucl Med · 2021-12-01

综述指出转移性前列腺癌仍属致死性疾病,PSMA因肿瘤高表达、正常组织低表达成为重要诊疗靶点。β和α发射的PSMA靶向放射性核素治疗(RNT)正在临床开发中,部分药物已显示良好活性,但存在原发和继发耐药,且对健康器官的影响限制治疗窗。文章概述现有PSMA靶向RNT及与新型内分泌药物、PARP抑制剂和免疫治疗联合的新策略。

要点

  • PSMA在前列腺癌及转移灶高表达、正常组织低表达,是诊疗一体化重要靶点。
  • β和α发射的PSMA靶向RNT均在临床开发,部分已显示良好活性。
  • 原发耐药和继发耐药不可避免,健康器官效应限制治疗窗。

核心结论

  • PSMA靶向RNT是转移性前列腺癌的重要治疗方向,联合策略有望提高疗效与安全性。

研究设计与样本

  • 综述,概述现有PSMA靶向RNT及与新型内分泌药物、PARP抑制剂和免疫治疗联合的临床前/临床研究。

主要发现

  • β和α发射的PSMA靶向RNT均在临床开发中,部分药物已显示良好活性。
  • 部分患者存在原发耐药,继发耐药不可避免。
  • PSMA靶向RNT对健康器官的影响限制其治疗窗。

关键数值与推荐

  • PSMA在前列腺癌细胞和转移灶显著过表达,正常组织表达低。

临床怎么用

  • 需阐明PSMA生物学及RNT药代/药效与耐药机制,以优化疗效和安全性。
  • 可关注PSMA靶向RNT与新型内分泌药物、PARP抑制剂和免疫治疗的联合研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite significant advances in therapeutic developments for prostate cancer over the last 2 decades, metastatic prostate cancer remains a lethal disease. Prostate-specific membrane antigen (PSMA), which is markedly overexpressed in prostate cancer cells and metastatic sites but has low normal-tissue expression, has emerged as an important theranostic target for this disease. Both β-emitting and α-emitting PSMA-targeted radionuclide therapy (RNT) are in clinical development. Several of these agents have already shown promising activity; however, a subset of patients have primary resistant disease, and secondary resistance invariably occurs. Further, the effect of these therapies on healthy organs limits their therapeutic window. Elucidating the biology of PSMA and characterizing the pharmacokinetic and pharmacodynamic properties of PSMA-targeted RNT and mechanisms of resistance will facilitate therapeutic approaches aimed at improving efficacy and safety. In this review, we provide an overview of existing PSMA-targeting RNT and novel RNT combinatorial approaches, such as those with novel hormonal agents, poly-[adenosine diphosphate-ribose]-polymerase inhibitors and immunotherapy, currently under investigation.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Sandhu S, Guo C, Hofman MS, et al. Radionuclide Therapy in Prostate Cancer: From Standalone to Combination PSMA Theranostics. J Nucl Med. 2021. PMID: 34385339. doi:10.2967/jnumed.120.243295

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。